Search - tctmd.com

Displaying 241 - 260 of 471

Sort: Relevancy | Date

News Daily News

Fewer MIs With Prasugrel Than Ticagrelor in STEMI Patients: ISAR-REACT 5

Michael O'Riordan

November 03, 2020

News Daily News

Failure to Access Coronaries After TAVR Almost Exclusive to CoreValve Evolut

Michael O'Riordan

October 28, 2020

News Daily News

More Risk of Death—All, Cardiac, and Noncardiac—With PCI Over Surgery: Meta-analysis

Michael O'Riordan

October 23, 2020

News Conference News TCT 2020

Under ISCHEMIA’s Long Shadow, Cardiologists Ponder Shifting Guidelines, Care

Michael O'Riordan

October 19, 2020

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

News Daily News

Hostility After ACS Linked to All-Cause Mortality

Michael O'Riordan

September 21, 2020

News Daily News

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

Michael O'Riordan

September 18, 2020

News Daily News

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Michael O'Riordan

September 16, 2020

News Conference News ESC 2020

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

Michael O'Riordan

August 31, 2020

News Daily News

Early Revascularization in NSTEMI Linked to Lower Mortality: AHRQ Analysis

Michael O'Riordan

August 20, 2020

News Daily News

Less MI, CV Death With Noninvasive Testing for Chest Pain: Observational Data

Michael O'Riordan

July 14, 2020

News Daily News

Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects

Michael O'Riordan

July 13, 2020

News Conference News EuroPCR 2020

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

Michael O'Riordan

June 30, 2020

News Conference News EuroPCR 2020

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

Michael O'Riordan

June 26, 2020

News Daily News

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

Michael O'Riordan

June 08, 2020

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

News Daily News

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Michael O'Riordan

May 05, 2020

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

News Daily News

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

Michael O'Riordan

April 27, 2020

News

As COVID-19 Spreads, US Cath Labs Ponder Fibrinolytics for STEMI

Michael O'Riordan

April 17, 2020

Advertisement

Fewer MIs With Prasugrel Than Ticagrelor in STEMI Patients: ISAR-REACT 5

Failure to Access Coronaries After TAVR Almost Exclusive to CoreValve Evolut

More Risk of Death—All, Cardiac, and Noncardiac—With PCI Over Surgery: Meta-analysis

Under ISCHEMIA’s Long Shadow, Cardiologists Ponder Shifting Guidelines, Care

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Hostility After ACS Linked to All-Cause Mortality

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

Early Revascularization in NSTEMI Linked to Lower Mortality: AHRQ Analysis

Less MI, CV Death With Noninvasive Testing for Chest Pain: Observational Data

Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

Possible Antithrombotic and Anti-inflammatory Therapies for COVID-19

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

As COVID-19 Spreads, US Cath Labs Ponder Fibrinolytics for STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content